Comparison of Emergence and Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia
NCT ID: NCT02324283
Last Updated: 2024-04-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
80 participants
INTERVENTIONAL
2012-10-31
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action
NCT05663242
Effect of Anesthetics on Oxygenation and Microcirculation During One-lung Ventilation
NCT02191371
Effects of Desflurane and Propofol During Lung Volume Reduction Surgery
NCT04226625
Comparison of Analgesic Effect of Volatile Anesthetics
NCT02830243
Comparison of Volatile Anesthetics on Cerebral Oxygenation During Controlled Hypotension
NCT02834845
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Transesophageal echocardiography (TEE) wiill be used to measure pulmonary blood flow during surgery visible and successively. To confirm the effect of HPV by measuring the change in pulmonary blood flow. The correlation between the blood oxygen concentration and attenuation of blood flow will be investigated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Desflurane
Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1\~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
desflurane
Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.
Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia.
Propofol
Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1\~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
propofol
Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
desflurane
Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.
Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia.
propofol
Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergoing lung cancer surgery requiring one-lung ventilation.
* American Society of Anesthesiologists Physical Status Class 1 or 2
Exclusion Criteria
* New York Heart Association Classification more than 2
* Respiratory dysfunction Vital Capacity or percent predicted Forced expiratory volume in one second is less than 50 %
* Pulmonary hypertension with mean pulmonary arterial pressure more than 30 mmHg
* Coagulation dysfunction
* The administration of steroids and immunosuppressive agents within 3 months prior to surgery
* Infection with active inflammation
* Pneumonectomy patients
* Cases of epidural anesthesia is contraindicated
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baxter Healthcare Corporation
INDUSTRY
Juntendo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eiichi Inada, M.D.
Role: PRINCIPAL_INVESTIGATOR
Juntendo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Juntendo
Bunkyō City, Tokyko, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-97
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.